Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
We support clients across the full lifecycle of strategic commercial arrangements, from structuring and negotiation through to implementation and ongoing optimisation, helping ensure agreements continue to align with evolving business priorities, market dynamics, and regulatory risk. We advise on complex, cross-border agreements, coordinating multi-jurisdictional input to deliver consistent, commercially effective outcomes. We also work closely with clients to design and maintain agreements that balance risk and opportunity, providing clear, practical guidance on how to align incentives, allocate value, and protect key assets - whether establishing new partnerships or refining existing relationships, to ensure long-term commercial success.
By collaborating closely with colleagues in our corporate, M&A, finance, tax, privacy, antitrust, and regulatory practices, we deliver integrated solutions to even the most complex arrangements. Whether you're a fast-growing start-up or a global market leader, we meet you where you need us most – with clarity, confidence, and a focus on your goals.
Our capabilities at a glance
400
+
IP lawyers and professionals
90
+
IP & technology transactions lawyers
50
%+
We represent more than half of the world's best 100 global brands, 2024 Interbrand Report
Key contacts
Representative experience
Advised a U.S. biotechnology company in collaboration with Chinese company and transfer of transgenic technology to Chinese-U.S. joint venture.
Advised Citrine on a drug license-in project with a French biological company, including reviewing its exclusive license agreement and advising on drug patent linkage matters in China.
Advised Global cosmetic companies such as Supergoop! and Glo Skin with respect to complex commercial agreements including international distribution and supply chain arrangements.
Advised multiple global clients on cross-border contracts, international sales and commercial law, and localization of contracts into national law.
Advised Tommy John on transactional and strategic advice, and their key commercial arrangements recently leading a worldwide team to advise on an international warehousing and distribution arrangement.
Advising a global technology company on its joint venture with a global pharma company to enable the research, development, and commercialization of bioelectronic medicines.
Advising Sandoz AG on a global collaboration with Biocon Biologics Limited, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology.
Represented Daiichi Sankyo its collaboration with Merck & Co. to develop and commercialize their U3-1402, DS-6000 and DS-7300 antibody-drug candidates.
Represented national REIT in data center value added services commercialization strategy.
Represented public-private partnership in the development and commercialization of a state-wide broadband network.
Awards and recognitions
Europe IP Transactions & Advisory Law Firm of the Year (Shortlist)
Managing IP EMEA Awards
2026
IP Transactions & Advisory Law Firm of the Year – Germany & Netherlands (Shortlist)
Managing IP EMEA Awards
2026
Firm of the Year IP Transactions - US (Shortlist)
Managing IP Americas Awards
2025
Americas Impact Deal of the Year
Managing IP Americas Awards
2024
